Shots:
- Grünenthal to acquire EU rights (Ex- Spain and the UK) of Crestor & its associated brands for ~$350M and will take over bulk production and packaging by 2025. The deal is expected to be closed in Q1’21
- The payments will be made in two tranches: $320M will be paid upon transaction closing and $30M as additional milestones
- Crestor is a statin, a lipid-lowering agent used to treat blood-lipid disorders & to prevent CV events, such as heart attacks & strokes, and is approved as a lipid-regulating medicine in 100+ countries
Click here to read full press release/ article | Ref: PRNewswire | Image: Wikipedia
The post AstraZeneca to Divest European Rights of Crestor (rosuvastatin) to Grünenthal for ~0M first appeared on PharmaShots.
